Copper chelator (oral)

Cuprimine (penicillamine)

Also marketed as Depen. An approved treatment for Wilson Disease.

FDA Approved (1970)by Bausch Health (Cuprimine); Viatris (Depen); generic available
Preclinical
Phase 1
Phase 2
Phase 3
Approved
1970
Drug facts

The same compound appears under different names depending on the context. Here is how to identify Penicillamine wherever you encounter it, plus the key facts at a glance.

Generic name
Penicillamine
Brand names
Cuprimine, Depen
Drug class
Copper chelator (oral)
Manufacturer
Bausch Health (Cuprimine); Viatris (Depen); generic available
How it's taken
Taken by mouth on an empty stomach.

The original copper chelator for Wilson disease, in clinical use since the 1950s. Highly effective at removing copper but limited by a substantial side effect burden, which has driven decades of effort to develop better-tolerated alternatives. Still widely used for initial de-coppering in many centers.

Where Penicillamine fits

Historical first-line de-coppering agent. Many centers now consider trientine (Cuvrior or Syprine/generic) or zinc as alternatives or first-line options for selected patients given penicillamine's tolerability profile, but penicillamine remains a standard option, particularly during the initial de-coppering phase.

How Penicillamine works

Oral copper chelator that binds copper and other heavy metals so they can be excreted in the urine. Penicillamine has been the historical first-line de-coppering agent for Wilson disease since the 1950s.

Side effects and safety

What patients report

Penicillamine has one of the broader side effect profiles in Wilson disease therapy. Common effects include rash, fever, lymphadenopathy, taste changes, and gastrointestinal upset, especially during initiation. Important serious effects include bone marrow suppression (cytopenias, requiring CBC monitoring), proteinuria from membranous nephropathy, drug-induced lupus and other autoimmune syndromes, myasthenia gravis, and pyridoxine (vitamin B6) deficiency that requires routine supplementation. Paradoxical worsening of neurologic symptoms during the first weeks of therapy can occur in patients with neurologic Wilson disease. Penicillamine has a boxed warning: it should never be used casually, every patient should stay under close supervision by a doctor who knows its risks, and any sign of a side effect should be reported right away. The label says deaths have occurred from aplastic anemia, agranulocytosis, low platelets, Goodpasture's syndrome (a kidney and lung disease) and myasthenia gravis. Urine tests and blood counts are done twice a week for the first month, every 2 weeks for the next 5 months, then monthly, and fever, sore throat, chills, bruising or bleeding should be reported right away. People who had aplastic anemia or agranulocytosis from penicillamine should not take it again. The label also warns about liver injury (liver tests every 3 months in the first year for Wilson disease), pemphigus (a serious blistering skin disease), a rare lung disease called obliterative bronchiolitis, and possible harm to an unborn baby.

This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.

Taking Penicillamine

Taken by mouth on an empty stomach. Adult de-coppering doses are typically 1000 to 1500 mg per day divided into 3 to 4 doses, lowered to a maintenance dose (often 750 to 1000 mg per day) once de-coppering is achieved. The label says people with Wilson disease should take 25 mg of pyridoxine (vitamin B6) a day during treatment, because penicillamine raises the need for it. Take penicillamine at least 1 hour before or 2 hours after meals, and at least 1 hour apart from other medicines, food, milk, antacids, zinc or iron.

Availability and cost

Generic available

Generic versions may be available at a lower cost. Ask your pharmacist.

Help paying for Cuprimine

Pick your insurance to see which help fits. Drugmaker copay cards can't be used with Medicare, Medicaid or TRICARE; charity funds are the usual route there.

Your insurance
From the drugmaker
Cuprimine (Penicillamine)
Some details not published
Bausch Health Patient Assistance Program
  • Free medicine program

    Brand CUPRIMINE is on the Bausch Health PAP list. Free medicine for eligible patients with limited or no coverage, shipped home for up to 1 year.

    For: no insurance, underinsured, Medicaid · source

Good to know: Applies to brand CUPRIMINE only; generic penicillamine and DEPEN (Mylan) are not covered. Bausch left certain federal Medicaid programs on Oct 1, 2025, so Medicaid may not cover Bausch brands; Medicaid patients may get them free through the PAP. A WD Rx Access copay form exists, but its posted terms expired, so current copay help is unconfirmed.

Checked on the drugmaker's official pages on September 24, 2026. Programs change; confirm with the program before you rely on it.
Charity funds for Wilson Disease
  • From a charity · Wilson Disease Association
    WDA Patient Assistance fund
    Apply directly

    Pays for: Travel and lodging (up to 7 days) for testing or treatment, for the patient and one companion, up to $2,000 per year.

    The foundation says: “Status not shown on page”
Status as each foundation showed it on September 28, 2026.

More ways to get help paying for treatment →

How Wilson disease treatments compare

Four FDA-approved medications are available for Wilson disease, plus several investigational programs in late-stage trials. Treatment choice depends on your stage (active de-coppering versus stable maintenance), your tolerance to penicillamine, whether you have neurologic or hepatic features, and your age. This chart summarizes the practical differences between the approved options.

4 FDA-approved wilson disease treatments are available: Cuprimine / Depen (penicillamine, approved 1956); Syprine (trientine hydrochloride, approved 1985); Galzin (zinc acetate, approved 1997); Cuvrior (trientine tetrahydrochloride, approved 2022). Cuprimine / Depen is typically used as historical first-line for active de-coppering. many centers now switch patients off due to side effect burden once stable..

DrugHow it worksHow it’s givenHow oftenWhere you take itTypical useFDA approved
Cuprimine / Depen
penicillamine
You are here
Copper chelator — binds copper in the body so it can be flushed out through the urine. The original Wilson disease drug.Oral capsule or tablet, taken on an empty stomach3–4 times daily during de-coppering, lower doses for maintenanceHome (oral)Historical first-line for active de-coppering. Many centers now switch patients off due to side effect burden once stable.1956
Syprine
trientine hydrochloride
Copper chelator — binds copper for urinary excretion. Generally better tolerated than penicillamine but similar efficacy.Oral capsule, taken on an empty stomach (capsules require refrigeration)2–4 times dailyHome (oral)Alternative chelator for patients who cannot tolerate penicillamine. Generic versions widely available.1985
Galzin
zinc acetate
Copper absorption blocker — induces a protein in the gut (metallothionein) that traps dietary copper before it can be absorbed.Oral capsule, taken on an empty stomach (separated from chelators)3 times dailyHome (oral)First-line maintenance therapy in many centers, particularly for presymptomatic patients identified through family screening.1997
Cuvrior
trientine tetrahydrochloride
Copper chelator — same chelating action as Syprine, with a more chemically stable salt formulation that allows simpler storage and twice-daily dosing.Oral tablet, taken on an empty stomachTwice dailyHome (oral)Approved for adults with stable Wilson disease who are de-coppered and tolerant to penicillamine; designed as a maintenance switch option.2022
Cuprimine / DepenThis drug
penicillamine · Bausch Health (Cuprimine), Mylan (Depen); generic available
MechanismCopper chelator — binds copper in the body so it can be flushed out through the urine. The original Wilson disease drug.
RouteOral capsule or tablet, taken on an empty stomach
Frequency3–4 times daily during de-coppering, lower doses for maintenance
WhereHome (oral)
Typical useHistorical first-line for active de-coppering. Many centers now switch patients off due to side effect burden once stable.
Approved1956
Syprine
trientine hydrochloride · Aton Pharma (originally Merck); generic available
MechanismCopper chelator — binds copper for urinary excretion. Generally better tolerated than penicillamine but similar efficacy.
RouteOral capsule, taken on an empty stomach (capsules require refrigeration)
Frequency2–4 times daily
WhereHome (oral)
Typical useAlternative chelator for patients who cannot tolerate penicillamine. Generic versions widely available.
Approved1985
Galzin
zinc acetate · Eton Pharmaceuticals (Galzin); generic available
MechanismCopper absorption blocker — induces a protein in the gut (metallothionein) that traps dietary copper before it can be absorbed.
RouteOral capsule, taken on an empty stomach (separated from chelators)
Frequency3 times daily
WhereHome (oral)
Typical useFirst-line maintenance therapy in many centers, particularly for presymptomatic patients identified through family screening.
Approved1997
Cuvrior
trientine tetrahydrochloride · Orphalan
MechanismCopper chelator — same chelating action as Syprine, with a more chemically stable salt formulation that allows simpler storage and twice-daily dosing.
RouteOral tablet, taken on an empty stomach
FrequencyTwice daily
WhereHome (oral)
Typical useApproved for adults with stable Wilson disease who are de-coppered and tolerant to penicillamine; designed as a maintenance switch option.
Approved2022

This chart summarizes approved Wilson disease treatments to help you understand the landscape. It is not medical advice. Treatment decisions depend on your individual disease stage, prior therapies, tolerability, and lab values for copper control. Investigational programs (ALXN1840, VTX-801, UX701) are not included because they are not yet FDA-approved. Always discuss options with your hepatologist or metabolic specialist.

Development history

Penicillamine was first reported as a copper chelator by John Walshe in 1956 and transformed Wilson disease from a fatal disease into a treatable one. It remained the only Wilson disease drug for nearly 30 years until trientine hydrochloride (Syprine) was approved in 1985, and is still in routine use today.

Ask anything about Penicillamine
AI-powered answers from clinical trial databases, FDA reports, and medical literature
Tap to start:
Or start with one of these

Explore Wilson Disease trials

Other Wilson Disease treatments

Common questions about Penicillamine

▸What is Penicillamine (Cuprimine)?

The original copper chelator for Wilson disease, in clinical use since the 1950s. Highly effective at removing copper but limited by a substantial side effect burden, which has driven decades of effort to develop better-tolerated alternatives. Still widely used for initial de-coppering in many centers.

▸What is the mechanism of action of Penicillamine?

Oral copper chelator that binds copper and other heavy metals so they can be excreted in the urine. Penicillamine has been the historical first-line de-coppering agent for Wilson disease since the 1950s.

▸What are the side effects of Penicillamine?

Penicillamine has one of the broader side effect profiles in Wilson disease therapy. Common effects include rash, fever, lymphadenopathy, taste changes, and gastrointestinal upset, especially during initiation. Important serious effects include bone marrow suppression (cytopenias, requiring CBC monitoring), proteinuria from membranous nephropathy, drug-induced lupus and other autoimmune syndromes, myasthenia gravis, and pyridoxine (vitamin B6) deficiency that requires routine supplementation. Paradoxical worsening of neurologic symptoms during the first weeks of therapy can occur in patients with neurologic Wilson disease. Penicillamine has a boxed warning: it should never be used casually, every patient should stay under close supervision by a doctor who knows its risks, and any sign of a side effect should be reported right away. The label says deaths have occurred from aplastic anemia, agranulocytosis, low platelets, Goodpasture's syndrome (a kidney and lung disease) and myasthenia gravis. Urine tests and blood counts are done twice a week for the first month, every 2 weeks for the next 5 months, then monthly, and fever, sore throat, chills, bruising or bleeding should be reported right away. People who had aplastic anemia or agranulocytosis from penicillamine should not take it again. The label also warns about liver injury (liver tests every 3 months in the first year for Wilson disease), pemphigus (a serious blistering skin disease), a rare lung disease called obliterative bronchiolitis, and possible harm to an unborn baby.

▸How is Penicillamine taken?

Taken by mouth on an empty stomach. Adult de-coppering doses are typically 1000 to 1500 mg per day divided into 3 to 4 doses, lowered to a maintenance dose (often 750 to 1000 mg per day) once de-coppering is achieved. The label says people with Wilson disease should take 25 mg of pyridoxine (vitamin B6) a day during treatment, because penicillamine raises the need for it. Take penicillamine at least 1 hour before or 2 hours after meals, and at least 1 hour apart from other medicines, food, milk, antacids, zinc or iron.

▸Is Penicillamine FDA approved?

Yes, Penicillamine (Cuprimine) is FDA approved (1970) for the treatment of Wilson Disease.

This page is for informational purposes only and does not constitute medical advice. Drug information is sourced from public databases and peer-reviewed literature and may not reflect the most recent updates. Always discuss treatment options with your healthcare provider. Last reviewed: September 2026.

Follow Penicillamine (Cuprimine) news by email

One email when Penicillamine (Cuprimine) has trial changes, FDA news, or label updates for its condition. No newsletter, no spam.

We never share your email. Unsubscribe anytime.